-
公开(公告)号:US11485796B2
公开(公告)日:2022-11-01
申请号:US16783720
申请日:2020-02-06
Applicant: GENMAB A/S
Inventor: Aran Frank Labrijn , Joyce I. Meesters , Joost J. Neijssen , Edward Norbert Van Den Brink , Janine Schuurman , Paul Parren
Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
-
公开(公告)号:US11459395B2
公开(公告)日:2022-10-04
申请号:US17172694
申请日:2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor: Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz , Edward Van den Brink , Dennis Verzijl
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号:US10968280B2
公开(公告)日:2021-04-06
申请号:US16779011
申请日:2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor: Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号:US20200079866A1
公开(公告)日:2020-03-12
申请号:US16582534
申请日:2019-09-25
Applicant: BIONTECH SE , GENMAB A/S
Inventor: Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号:US10544220B2
公开(公告)日:2020-01-28
申请号:US15541594
申请日:2016-01-08
Applicant: GENMAB A/S
Inventor: Patrick Engelberts , Esther Breij , Rik Rademaker , Isil Altintas , David Satijn , Sandra Verploegen , Riemke Van Dijkhuizen Radersma , Edward Van Den Brink , Janine Schuurman , Paul Parren
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61K39/00
Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
-
公开(公告)号:US10351629B2
公开(公告)日:2019-07-16
申请号:US15072983
申请日:2016-03-17
Applicant: GENMAB A/S
Inventor: Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Paul Parren , Willem Karel Bleeker , Frank Beurskens , Patrick Van Berkel
Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
-
公开(公告)号:US20190160170A1
公开(公告)日:2019-05-30
申请号:US16270317
申请日:2019-02-07
Applicant: GENMAB A/S
Inventor: Esther Breij , David Satijn , Edward Norbert Van Den Brink , Dennis Verzijl , Rob N. De Jong , Paul Parren , Riemke Van Dijkhuizen Radersma
IPC: A61K39/395 , C07K16/28 , A61K47/68 , C07K16/30
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
48.
公开(公告)号:US09492565B2
公开(公告)日:2016-11-15
申请号:US14854613
申请日:2015-09-15
Applicant: GENMAB A/S
Inventor: David Satijn , Sandra Verploegen , Wim Bleeker , Steen Lisby , Jan Van De Winkel , Patrick Van Berkel , Paul Parren
IPC: A61K39/395 , A61K47/48 , C07K16/36 , A61K45/06 , C07K16/30
CPC classification number: A61K47/48561 , A61K45/06 , A61K47/6817 , A61K47/6849 , C07K16/30 , C07K16/36 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物,以及使用抗体和抗体药物偶联物的治疗和诊断方法。
-
公开(公告)号:US12077596B2
公开(公告)日:2024-09-03
申请号:US17360438
申请日:2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor: Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Friederike Gieseke , Ugur Sahin
IPC: C07K16/28 , A61K39/395 , G01N33/569
CPC classification number: C07K16/2878 , A61K39/3955 , G01N33/56972 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号:US11970544B2
公开(公告)日:2024-04-30
申请号:US17353087
申请日:2021-06-21
Applicant: GENMAB A/S
Inventor: David Satijn , Esther C. W. Breij , Bart E. C. G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
CPC classification number: C07K16/30 , A61P35/00 , C12N15/79 , A61K2039/505 , C07K2317/31 , C07K2317/51 , C07K2317/565
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
-
-
-
-
-
-
-
-